COMPANY PROFILE / #3309
Epikast
New York, NYVenture Capital-Backed
OVERVIEW
Developer of a healthcare engagement platform designed to create personalized experiences for patients, physicians, and other healthcare professionals and caregivers. The company's platform offers services that focus on minimizing the bureaucratic and administrative burden for patients and physician offices and redefining how biopharmaceutical companies engage with stakeholders, enabling physicians to improve overall patient engagement and outcomes.
已融资11.50
最新估值37.20
员工数60
成立年份2022
公司概况
- Companies
- Epikast
- Description
- Developer of a healthcare engagement platform designed to create personalized experiences for patients, physicians, and other healthcare professionals and caregivers. The company's platform offers services that focus on minimizing the bureaucratic and administrative burden for patients and physician offices and redefining how biopharmaceutical companies engage with stakeholders, enabling physicians to improve overall patient engagement and outcomes.
- Website
- www.epikast.com
- HQ Location
- New York, NY
- Year Founded
- 2022
- Keywords
- clinical trial support, engagement platform, healthcare engagement platform, medical science liaisons, patient engagement, patient engagement service, pharma sales force, reimbursement support
- Competitors
- Inizio, IQVIA, Lash Group, EVERSANA, Sonexus Health, AssistRx, IMS Health Holdings, Syneos Health, CareMetx, Ashfield Healthcare, Indegene
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 11.50
- First Financing Date
- 16-Feb-2023
- First Financing Size
- 10.00
- First Financing Valuation
- 25.00
- Last Financing Date
- 30-Jan-2026
- Last Financing Deal Type
- Early Stage VC
- Last Financing Size
- 1.50
- Last Financing Valuation
- 37.20
- Last Financing Status
- Completed
- Last Known Valuation
- 37.20
- Last Known Valuation Date
- 30-Jan-2026
- Last Known Valuation Deal Type
- Early Stage VC
- Valuation Estimate
- 51.06
- Valuation Estimate Growth Rate
- 37.26%
- Active Investors
- EcoR1 Capital, Kos Biotechnology Partners, Synetro Group
- # Active Investors
- 3
- Acquirers
- —
团队与联系人
- Employees
- 60
- Employee Growth %
- 122.22%
- Employee History
- 2026: 60, 2025: 27, 2024: 21, 2023: 15
- Primary Contact
- Vangelis Vergetis
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- vangelis.vergetis@epikast.com
- Primary Contact Phone
- +1 (212) 970-8797
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 8%
- Success Probability Over Time – 3 Year
- 40%
- Success Probability Over Time – 5 Year
- 62%
记录来源：public.companies · 原始序号 #3309 · 所有字段均按数据库原值展示。